Loading...
•
Sep 30
AbbVie Q3 2025 Earnings Report
AbbVie reported strong Q3 2025 results with revenue and adjusted EPS growth driven by Immunology and Neuroscience portfolios.
Key Takeaways
AbbVie delivered $15.776 billion in quarterly revenue and an adjusted EPS of $1.86, showing solid growth from Immunology and Neuroscience segments, partially offset by Oncology and Aesthetics softness.
Immunology revenue reached $7.885B, driven by Skyrizi and Rinvoq.
Neuroscience portfolio grew 20.2%, led by Vraylar and Botox Therapeutic.
Oncology sales declined slightly due to Imbruvica performance.
Adjusted operating margin stood at 30.9%, with a 24.5% adjusted tax rate.
AbbVie
AbbVie
AbbVie Revenue by Segment
AbbVie Revenue by Geographic Location
Revenue by Segment
Immunology Revenue
CapyFin.comNeuroscience Revenue
CapyFin.comOncology Revenue
CapyFin.comAesthetics Revenue
CapyFin.comEye Care Revenue
CapyFin.comOther Key Products Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
AbbVie raised its full-year 2025 adjusted EPS guidance to $10.61–$10.65, reflecting solid performance in key therapeutic areas and continued pipeline advancement.
Positive Outlook
- Raised full-year adjusted EPS guidance to $10.61–$10.65
- Strong Skyrizi and Rinvoq performance
- Neuroscience segment growing at over 20%
- Dividend increase of 5.5% announced for 2026
- Progress in advancing new therapies across pipeline
Challenges Ahead
- High GAAP tax rate of 73.7%
- Imbruvica revenue decline of nearly 15%
- Humira global revenue dropped 55%
- Aesthetics segment declined 3.7%
- Continued IPR&D and milestone expenses impacting net income